Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAAC trial: Anticoagulant Therapy in patients with atrial fibrillation after surgical Left Atrial Appendage Closure
2022-502986-92-00Phase 4Authorised
- Sponsor
- University Hospital Odense
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised trial of apixaban, rivaroxaban, edoxaban, warfarin and dabigatran in Atrial fibrillation (AFib) and atrial flutter (AFL) (2 arms), sponsored by University Hospital Odense. Primary endpoint: Composite of stroke, peripheral embolisms and major bleeding events. Planned start Jun 2023; status: authorised.
02
Drugs
apixabanrivaroxabanedoxabanwarfarindabigatran
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on 2022-502986-92-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502986-92-00.